In clinical trials of an allergy medicine, 3302 allergy sufferers were randomly assigned to either a medicine group or a placebo group. It was reported that 49 out of 1654 individuals in the medicine group and 30 out of 1648 individuals in the placebo group experienced dry mouth as a side effect of their respective treatments, Complete parts (a) through (). (a) What type of experimental design is this? O A. Randomized block design O B. Completely randomized design O C. Matched-pairs design O D. It cannot be determined with the information given. (b] What is the response variable in this study? Is it qualitative or quantitative ? The response variable is whether or not a subject (c) What is the explanatory variable? How many levels does the treatment have? The explanatory variable is it has (d) The clinical trial was double-blind. What does this mean? O A. Neither the subject nor the individual monitoring the subject knows relieve allergy symptoms. O B. Neither the subject nor the individual monitoring the subject knows if the subject is receiving the medicine or the placebo, O C. The individual monitoring the subject does not know whether or not the subject suffers from allergies, and the subject does not know if they are receiving the medicine or the placebo O D. The individual monitoring the subject does not know whether or not the subject has dry mouth, and the subject don't not know if they are receiving the medicine or the placebo. (e) Why is it important to have a placebo group? Select all that apply A. Fewer people are harmed if the medicine turns out to be harmful Click to select your answer(s)